p53 Gene Therapy in Treatment of Diabetes Concurrent With Hepatocellular Carcinoma
Status:
Unknown status
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
An open-labeled phase II study to investigate preliminary efficacy using p53 gene therapy in
treatment of diabetes concurrent with hepatocellular carcinoma (HCC).